- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- ALEMBIC PHARMACEUTICALS LTD. (pharmaceuticals)
- Latest 8 Quarter Result
ALEMBIC PHARMA Quarterly Results 
(APLL)
Here are the latest quarterly results of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA financial fact sheet and ALEMBIC PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
ALEMBIC PHARMA Quarterly Results
| No. of Mths Qtr. Ending |
3
Jun-16* |
3
Sep-16* |
3
Dec-16* |
3
Mar-17* |
3
Jun-17* |
3
Sep-17* |
3
Dec-17* |
3
Mar-18* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 7,280 | 8,794 | 7,770 | 7,414 | 6,482 | 7,893 | 8,400 | 8,533 | |
| Other income | Rs m | 4 | 5 | 2 | 9 | 2 | 77 | 3 | 6 | |
| Turnover | Rs m | 7,284 | 8,799 | 7,772 | 7,422 | 6,484 | 7,970 | 8,404 | 8,540 | |
| Expenses | Rs m | 5,711 | 7,016 | 6,316 | 6,086 | 5,468 | 6,101 | 6,525 | 6,801 | |
| Gross profit | Rs m | 1,571 | 1,741 | 1,476 | 1,347 | 1,014 | 1,791 | 1,875 | 1,730 | |
| Depreciation | Rs m | 194 | 206 | 211 | 218 | 218 | 257 | 264 | 316 | |
| Interest | Rs m | 11 | 10 | 8 | 18 | 9 | 4 | 8 | 13 | |
| Profit before tax | Rs m | 1,370 | 1,530 | 1,258 | 1,119 | 789 | 1,608 | 1,606 | 1,408 | |
| Tax | Rs m | 333 | 332 | 393 | 165 | 155 | 366 | 298 | 385 | |
| Profit after tax | Rs m | 1,037 | 1,198 | 866 | 954 | 634 | 1,242 | 1,309 | 1,022 | |
| Gross profit margin | % | 21.6 | 19.8 | 19.0 | 18.2 | 15.6 | 22.7 | 22.3 | 20.3 | |
| Effective tax rate | % | 24.3 | 21.7 | 31.2 | 14.7 | 19.6 | 22.7 | 18.5 | 27.4 | |
| Net profit margin | % | 14.2 | 13.6 | 11.1 | 12.9 | 9.8 | 15.7 | 15.6 | 12.0 | |
| Diluted EPS | Rs | 5.5 | 6.4 | 4.6 | 5.1 | 3.4 | 6.6 | 6.9 | 5.4 | |
| Diluted EPS (TTM) | Rs | 40.0 | 31.0 | 21.3 | 21.5 | 19.4 | 19.6 | 22.0 | 22.3 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
More Pharmaceuticals Company Quarterly Results: DR. REDDYS LAB CIPLA WYETH LTD GLENMARK PHARMA CADILA HEALTHCARE
Compare ALEMBIC PHARMA With: DR. REDDYS LAB CIPLA WYETH LTD GLENMARK PHARMA CADILA HEALTHCARE
Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends Volatile Day Flat; Realty Stocks Top Losers(Closing)
After opening the day in green and scaling new all-time high levels, share markets in India witnessed volatile trading activity throughout the day and ended the day flat.
Views on news
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
Has A Bank Ever Told You Its Deposits are Riskier than Stocks? These Should Have...(The 5 Minute Wrapup)
Jul 3, 2018Left on their own, the banks would possibly have to mark down the value of deposits by 90% to 100%.
The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)
Jul 4, 2018The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.
The 5-Point Checklist to Save You from Toxic Stocks(Profit Hunter)
Jul 2, 2018Worried about investing in one of the poisonous stocks that keep emerging from the woodwork? This checklist could come to your rescue
New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)
Jul 6, 2018ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.
When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)
Jul 6, 2018Buy Companies that can fight all kinds of Pandas and Bears in the long run.
More|
| |
ALEMBIC PHARMA SHARE PRICE
Jul 13, 2018 (Close)
TRACK ALEMBIC PHARMA
- Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ALEMBIC PHARMA
ALEMBIC PHARMA - ADCOCK INGRAM COMPARISON
COMPARE ALEMBIC PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.